Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know.
about
Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsBiomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studiesThe assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data.Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics.Small-cell lung cancer with recurrent syncope as the initial symptom: A case report and literature review.10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation studyOptimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome.Clinical utility of quantitative imaging.State of the art: Response assessment in lung cancer in the era of genomic medicineImaging guidelines and findings of extracranial glioblastoma.RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.Update on the role of imaging in management of metastatic colorectal cancerCancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic CancerCT perfusion as an imaging biomarker in monitoring response to neoadjuvant bevacizumab and radiation in soft-tissue sarcomas: comparison with tumor morphology, circulating and tumor biomarkers, and gene expression.Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.Novel agents in renal carcinoma: a reality check.Informatics in radiology: improving clinical work flow through an AIM database: a sample web-based lesion tracking application.miR-339-3p inhibits proliferation and metastasis of colorectal cancerPhase II Clinical Trial of Robotic Stereotactic Body Radiosurgery for Metastatic Gynecologic MalignanciesSystemic treatment in breast cancer: a primer for radiologistsVolumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or GefitinibRadiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitorsImage-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory trackingA prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer.Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment.RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.Pancreatic ductal adenocarcinoma staging.RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma.Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progressionComparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer.Salvage intraperitoneal chemotherapy for relapsed type II endometrial cancer: A pilot case-control study.
P2860
Q26822432-ACC9892E-EBE8-4FBB-AD39-1FD8FC9C0D7BQ27852062-7C3277E8-D077-481E-9FDF-BC53EE59909EQ28829200-E648C8C8-3B88-4746-ADDC-589A54768D46Q30882874-38A6A051-D6A6-49E8-9567-AB6D1735E345Q30913383-D60A7030-E518-4F52-A9B7-E3C71D9DE7D9Q33167950-AAC80139-03FD-407C-AC27-11B543AC0B49Q33577856-5DEC5BB8-197B-4898-804E-EC4B3FE6A9FCQ33830113-24E91413-61B8-4422-B117-EFDFCF7D0F22Q33845387-1039C4D3-9AC2-4E1E-A606-4740ECC6A451Q34537285-E74C8284-67BC-447C-8374-F2EBE9F24506Q34656915-F517AE6F-AF75-4C71-8ADC-6D9DD11D75E6Q34681069-639E8F08-977E-4D5F-A6B5-3AD160D3565BQ35099343-305C742E-4FAA-4E38-9ADC-B78BF1B88BD2Q35156636-EE8E6F28-172A-4ECD-923D-4FAED42871A2Q35285305-1DE3159A-939B-4B84-AF70-F0C50E3FD4D9Q35668604-584C2F1C-DBB0-477E-B192-F08576786395Q35686711-6A8ACC0B-ED0A-4E46-8814-3A7294A37292Q35776891-2F64F309-7E5D-43BE-B1DB-5E4FDC6A311FQ35821594-D1766153-5236-4A0D-A1CD-1AFC773B51EDQ36031518-BAFB41CC-00C8-4830-B2C9-26EE6A50FA5CQ36061173-E814F60F-A3C9-4467-B4F8-A11365B3A2F0Q36227680-CF03DA28-D9D2-4D2B-A520-CCE9F19FF392Q36335831-64171F30-6362-4377-B61D-D4DE8F93CAB4Q36446268-8257AD19-D86A-449B-B8F5-C489A1B677D8Q36510679-FB553AE7-845F-4912-A0D6-C8170058332DQ36553854-E5D01FA6-6F55-46B8-BDCA-6AEA9DF1746AQ36634305-349D97D7-440F-47E2-A1FB-6E5943E412A5Q36769581-BF383C3C-BB01-4ECB-985F-A002A1D929FCQ36778075-48A3F448-B03D-4883-A258-9E3FEA6D0B16Q36784065-056F0006-0CA2-47E0-B96E-FE743CB125C2Q36897213-B941FC80-777C-4BED-8EDC-6ADC0A89430BQ37021940-C606C5CE-9D9C-41C7-8C2E-D62D15FA2C31Q37024590-DB710F96-4F1B-453C-9DBF-F15D886F6B0CQ37065818-FD9688D9-1E83-4A95-A3E9-1B82DE55EA66Q37088281-08DF7D20-4A80-4A30-9017-1CECAD1D09C3Q37193819-4D0BE479-66B1-4432-AF88-B6590FF5058CQ37211774-FD9FDBB5-3236-4931-B8B7-A9278A9781C5Q37280018-30A61827-2399-46CF-80FE-AEC7A7831137Q37413611-333BFC57-234F-4FAE-A2A2-CE77722BE42DQ37489450-E6892E00-5FE9-4F77-B0EF-D8B9587F3151
P2860
Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Revised RECIST guideline versi ...... hat radiologists need to know.
@en
Revised RECIST guideline versi ...... hat radiologists need to know.
@nl
type
label
Revised RECIST guideline versi ...... hat radiologists need to know.
@en
Revised RECIST guideline versi ...... hat radiologists need to know.
@nl
prefLabel
Revised RECIST guideline versi ...... hat radiologists need to know.
@en
Revised RECIST guideline versi ...... hat radiologists need to know.
@nl
P2093
P356
P1476
Revised RECIST guideline versi ...... hat radiologists need to know.
@en
P2093
Annick D Van den Abbeele
Jyothi P Jagannathan
Mizuki Nishino
Nikhil H Ramaiya
P304
P356
10.2214/AJR.09.4110
P407
P577
2010-08-01T00:00:00Z